Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women
NCT ID: NCT02868905
Last Updated: 2016-08-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
160 participants
INTERVENTIONAL
2016-09-30
2018-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Of obese young adults and healthy young adults
* Of obese young adults and individuals affected by Alzheimer's disease (AD) having been obese at young adult age (\<50 years old) or individuals affected by Alzheimer's disease (AD) having never been obese.
The secondary purpose is to determine if there is an association between the frequency of these epigenetic markers and elements associated to the metabolic syndrome (lipidic and glycemic analysis, leptinemia, inflammation markers) and clinical ones (visceral fat mass, body mass index) in young adults.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Cohort Research of Genetic Susceptibility for Common Obesity in Women
NCT01488903
Evaluation Of DNA Methylation Pattern In Healthy, Sarcopenic, Obese And Sarcopenic Obese Older Women: A Cross-Sectional Study
NCT06618430
Physical and Behavioral Traits of Overweight and Obese Adults
NCT00428987
Investigation of Genetic Marker Associated With Obesity in Koreans
NCT01341860
A Biological Atlas of Severe Obesity (Biological Tissue Collection)
NCT01129297
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control group
Control group
Blood sample
Obese group
Obese group
Blood sample
Non-obese AD group
Non-obese AD groups
Blood sample
Obese AD group
Obese AD group
Blood sample
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood sample
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18-50 year old women, age- (10 years) and sociocultural-matched with group 2
* Non obese and never been obese
* 18.5 \< BMI \< 25
* Folstein MMS \> 27
* Informed consent
* Affiliation to social security plan
Group 2:
* 18-50 year old women, age- (10 years) and sociocultural-matched with group 1
* Waist size \> 88cm
* 30 \< BMI \< 45
* Insulin-resistant patients (Insulin resistance index, HOMA-IR \> 3.8)
* Obesity onset during childhood (pre-puberty period)
* Folstein MMS \> 27
* Informed consent
* Affiliation to social security plan
Group 3:
* \>60 year old women, age- (10 years) matched with group 4
* No obesity history (18.5 ≤ BMI \< 25 at adult age)
* Sporadic forms of mild to moderate AD with demonstration of AD physiopathologic process according to new recommendations of 2011 of National Institute on Aging and Alzheimer's Association on diagnostic guidelines for Alzheimer's disease
* 15\< Folstein MMS ≤ 26
* Informed consent
* Affiliation to social security plan
Group 4:
* \>60 year old women, age- (10 years) matched with group 3
* Obesity history (BMI \> 30 at least one time at adult age)
* Sporadic forms of mild to moderate AD with demonstration of AD physiopathologic process according to new recommendations of 2011 of National Institute on Aging and Alzheimer's Association on diagnostic guidelines for Alzheimer's disease
* 15 \< Folstein MMS ≤ 26
* Informed consent
* Affiliation to social security plan
Exclusion Criteria
* \<18
* Patient under guardianship, curatorship or judicial protection
* Folate supplementation
* Diabetic or glucose intolerant subjects
* Present participation to another study with neuropsychological evaluation and/or drug administration
* Pregnant women
Groups 2,3 and 4:
* \<18
* Patient under guardianship, curatorship or judicial protection
* Folate supplementation
* Present participation to another study with neuropsychological evaluation and/or drug administration
Group 2:
\- Pregnant women
Group 4:
\- Obese or overweight patients (BMI\>25)
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central Hospital, Nancy, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thérèse RIVASSEAU-JONVEAUX
Role: PRINCIPAL_INVESTIGATOR
Service de Gériatrie, Hôpitaux de Brabois, 3 rue du Morvan, 54 511 Vandoeuvre-lès-Nancy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHRU de Nancy
Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2015-A01686-43
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.